Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?

被引:4
|
作者
Capoor, Manu N. [1 ,2 ]
Ahmed, Fahad S. [3 ]
McDowell, Andrew [4 ]
Slaby, Ondrej [5 ,6 ]
机构
[1] Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA
[2] MMF Syst Inc, Execut Off, New York, NY 10022 USA
[3] MyMedicalFiles MMF Syst Inc, Data Sci & Engn, New York, NY USA
[4] Ulster Univ, Sch Biomed Sci, Nutr Innovat Ctr Food & Hlth NICHE, Coleraine, Londonderry, North Ireland
[5] Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic
[6] Masaryk Univ, Dept Biol, Fac Med, Brno, Czech Republic
关键词
SARS-CoV-2; COVID-19; T-cell; human coronaviruses; immunity; contact tracing; children; COVID-19; CHILDREN;
D O I
10.3389/fcimb.2020.605334
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The discovery of T-cell responses to SARS-CoV-2 in non-infected individuals indicates cross-reactive immune memory from prior exposure to human coronaviruses (HCoV) that cause the common cold. This raises the possibility that "immunity" could exist within populations at rates that may be higher than serology studies estimate. Besides specialized research labs, however, there is limited ability to measure HCoV CD4+ and CD8+ T-cell responses to SARS-CoV-2 infection, which currently impedes interpretation of any potential correlation between COVID-19 disease pathogenesis and the calibration of pandemic control measures. Given this limited testing ability, an alternative approach would be to exploit the large cohort of currently available data from which statistically significant associations may be generated. This would necessitate the merging of several public databases including patient and contact tracing, which could be created by relevant public health organizations. Including data from both symptomatic and asymptomatic patients in SARS-CoV-2 databases and surveillance systems could provide the necessary information to allow for more informed decisions.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Fighting the Battle against SARS-CoV-2 as Gastroenterologists in Italy
    Pagnini, Cristiano
    Urgesi, Riccardo
    Di Paolo, Maria Carla
    Graziani, Maria Giovanna
    GASTROENTEROLOGY, 2020, 159 (04) : 1619 - 1619
  • [2] The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2
    Garrido, Pablo F.
    Calvelo, Martin
    Blanco-Gonzalez, Alexandre
    Veleiro, Uxia
    Suarez, Fabian
    Conde, Daniel
    Cabezon, Alfonso
    Pineiro, Angel
    Garcia-Fandino, Rebeca
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 588
  • [3] The global battle against SARS-CoV-2 and COVID-19
    Deng, Chu-Xia
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (10): : 1676 - U96
  • [4] Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?
    Meyerholz, David K.
    Perlman, Stanley
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (01):
  • [5] SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial?
    Pinky, Lubna
    Dobrovolny, Hana M.
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2623 - 2630
  • [6] Symptomic Mimicry Between SARS-CoV-2 and the Common Cold Complex
    Turecek, Petr
    Kleisner, Karel
    BIOSEMIOTICS, 2022, 15 (01) : 61 - 66
  • [7] Symptomic Mimicry Between SARS-CoV-2 and the Common Cold Complex
    Petr Tureček
    Karel Kleisner
    Biosemiotics, 2022, 15 : 61 - 66
  • [8] From nature to medicine: bioactive compounds in the battle against SARS-CoV-2
    Sathishkumar, Kuppusamy
    NATURAL PRODUCT RESEARCH, 2024,
  • [9] The continued global battle against SARS-CoV-2 and COVID-19
    Deng, Chu-Xia
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (06): : 1440 - 1442
  • [10] The development of neutralizing antibodies against SARS-CoV-2 and their common features
    Liu, Liu Daisy
    Lian, Chaoyang
    Yeap, Leng-Siew
    Meng, Fei-Long
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2020, 12 (12) : 980 - 986